2nd DSTU Draft For Comment

This page is part of the FHIR Specification (v0.4.0: DSTU 2 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions

1.22.4.1.1070 v3 Code System substanceAdminSubstitution

This code system (http://hl7.org/fhir/v3/substanceAdminSubstitution) is defined as part of HL7 v3.

Formal value Set definition (identifier http://hl7.org/fhir/v3/vs/substanceAdminSubstitution): XML or JSON

Release Date: 2014-12-11

OID for code system: 2.16.840.1.113883.5.1070

1.22.4.1.1070.1 Description

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

LevelCodeDisplayDefinition
1(_ActSubstanceAdminSubstitutionCode)  Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
2  E equivalent Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
3    EC equivalent composition Description:
Substitution occurred or is permitted with another product that is a:
pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples:
Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
4      BC brand composition Description:
Substitution occurred or is permitted between equivalent Brands but not Generics
Examples:
Zestril for Prinivil Coumadin for Jantoven
4      G generic composition Description: Substitution occurred or is permitted between equivalent Generics but not Brands
Examples:
Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
3    TE therapeutic alternative Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.
Examples:
ranitidine for Tagamet
4      TB therapeutic brand Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics
> Examples:
Zantac for Tagamet
4      TG therapeutic generic Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands
> Examples:
Ranitidine for cimetidine
2  F formulary Description: This substitution was performed or is permitted based on formulary guidelines.
2  N none No substitution occurred or is permitted.